Lupin Limited (LUPIN) — Financial Results | 12 November 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Lupin Limited reported record Q2 FY2026 results with total revenue of ₹7,048 crores and EBITDA of ₹2,138 crores, marking 13 consecutive quarters of YoY growth. Revenue grew 24% YoY while EBITDA surged 63% YoY, with margins expanding 750 bps to 31.3%. U.S. business grew 47% YoY (USD 315 million), India grew 3.4% YoY, and Emerging Markets grew 45% YoY. Regulatory approvals included generic Victoza and Risperdal LAI. Net cash position strengthened to ₹1,665 crores from ₹310 crores. Management raised FY26 EBITDA margin guidance and expects 24-25% margins in FY27, with planned investments including USD 250 million Coral Springs manufacturing facility.

📄 View Original Announcement (PDF)

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

📊 More LUPIN filings

See all LUPIN filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track LUPIN — Free

Free account · 2 AI queries/day